Bone marrow pH and multiple myeloma progression in veterans
Official title: Critical role of bone marrow pH as a determinant of multiple myeloma progression and treatment
Funded at VA Greater Los Angeles Healthcare System · NIH-11412885 · Data updated 2026-11-12
This project looks at how the acidity inside bone marrow affects how multiple myeloma behaves and responds to treatment in veterans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| NIH project number | 1I01RD001409-01A2 |
| Project ID | NIH-11412885 on NIH RePORTER |
Who could benefit from this research
✓Could help
Veterans with multiple myeloma or MGUS who are treated at VA facilities and whose bone marrow biology could be influenced by pH-related mechanisms.
✕Less likely to help
Patients without myeloma or MGUS or those not receiving VA-based care may not benefit directly.
What this research studies
This research focuses on the role of bone marrow pH in myeloma biology and treatment responses. It will explore how acidic conditions in the bone marrow may help myeloma cells survive and resist therapy. The study aims to connect patient factors like age, race, and exposure history (e.g., Agent Orange) with disease biology to improve VA patient care. By understanding pH-related pathways, researchers hope to identify new approaches to prevent relapse and prolong remission for veterans with myeloma.
Why it matters
Potential benefit: If successful, the work could lead to new strategies that slow progression and improve treatment effectiveness for veterans with myeloma.
How similar studies have gone: Prior research has shown bone marrow pH and tumor microenvironment influence myeloma behavior, but durable translations to therapy are still under investigation.
Where this research is happening
-
VA Greater Los Angeles Healthcare System
Los Angeles, United States Active
Researchers
- Principal investigator: Frost, Patrick J — VA Greater Los Angeles Healthcare System
- Study coordinator: Frost, Patrick J
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.